Footnotes  A solid line spanning the margins will separate the body of the data display from the footnotes.  All footnotes will be left justified with single-line spacing immediately below the soli d line underneath the data display.  Footnotes should always begin with “Note:” if an informational footnote, or 1, 2, 3, etc. if a reference footnote. Each new footnote should start on a new line where possible.  Footnotes will be present on the page where they are first referenced and thereafter on each page of the table, unless the footnote is specific only to certain pages. Patient specific footnotes should be avoided.  Footnotes will be used sparingly and must add value to the table, figure, or data listing. If more than six lines of footnotes are planned, then a cover page may be used to display footnotes, and only those essential to comprehension of the data will be repeated on each page.  The last line of the footnote section will be a standard source line that indicates the nam e of the program used to produce the data display, date the program was run, and the listing source (ie, ‘Program : myprogram.sas Listing source: 16.x.y.z’). DocuSign Envelope ID: B3F56764-C440-4885-BA44-7578C4A73DB3 Stemline Therapeutics, Inc. Protocol: STML- 701-0114 Version 3.0, 10-JUL-2015 (Amendment 2) Statistical Analysis Plan Page 50 of 63 14. QUALITY CONTROL SAS programs are developed to produce clinical trial output such as analysis data sets, summary tables, data listings, figures or statistical analyses. TCM Groups is responsible for the quality control. Quality control is defined here as the operational techniques and activities undertaken to verify that the SAS programs produce the proper clinical trial outputs by checking for their logic, efficiency, and commenting, and by review of the produced output. DocuSign Envelope ID: B3F56764-C440-4885-BA44-7578C4A73DB3 Stemline Therapeutics, Inc.